TrialShock (Augusta, Ga.)2020
Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study.
Eizo Watanabe et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
46 papers cite it
this paperpooled itcites it